首页> 外文期刊>Seizure: the journal of the British Epilepsy Association >Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit.
【24h】

Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit.

机译:Sulthiame在难治性小儿癫痫病中的应用:在小儿神经病学部门使用“抗癫痫药”的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Sulthiame is an old antiepileptic drug primarily used in a few European countries for the treatment of benign epilepsy of childhood with central temporal spikes. Other studies suggest that it might be effective in children and adults with a range of refractory seizure types. METHODS: A retrospective case note review was undertaken to evaluate the efficacy and safety of sulthiame as adjunctive therapy in children with refractory epilepsies. RESULTS: Twenty patients (10 female) were evaluated, aged 10.7 (range 2.1-17) years. The median duration of treatment with sulthiame was 18 (range 2-37) months. Fifty five percent of patients showed at least a 50% reduction in seizure frequency and two patients were seizure-free at the end of follow-up. Patients with focal seizures responded best. Seven patients reported side effects, leading to withdrawal of the drug in two (10%). CONCLUSION: Sulthiame was reasonably effective and well-tolerated in a heterogeneous group of 20 children with refractory epilepsies. Although an 'old' antiepileptic drug it should be considered in a similar population.
机译:用途:Sulthiame是一种古老的抗癫痫药,主要在欧洲一些国家使用,用于治疗患有中央颞尖峰的儿童的良性癫痫。其他研究表明,它可能对患有多种难治性癫痫发作类型的儿童和成人有效。方法:回顾性病例记录研究评估了舒马胺作为辅助疗法治疗难治性癫痫儿童的疗效和安全性。结果:评估了20例患者(10例女性),年龄10.7岁(范围2.1-17)。苏丹舒马的中位治疗时间为18(2-37个月)。 55%的患者癫痫发作频率至少降低了50%,两名患者在随访结束时无癫痫发作。局灶性癫痫患者反应最好。 7名患者报告了副作用,导致有2名患者撤药(10%)。结论:在异质性20例难治性癫痫患儿中,Sulthiame相当有效且耐受性良好。尽管是“老”抗癫痫药,但应在相似人群中考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号